HIV infection can be effectively treated by lifelong administration of combination antiretroviral
therapy, but an effective vaccine will likely be required to end the HIV epidemic. Although the …

BACKGROUND A central challenge to emerging efforts to cure HIV infection is the
persistence of quiescent but replication-competent proviral genomes in resting CD4+ T …

Abstract HIVACAT T-cell immunogen (HTI) is a novel human immunodeficiency virus (HIV)
vaccine immunogen designed to elicit cellular immune responses to HIV targets associated …

Plant-made or “biofarmed” viral vaccines are some of the earliest products of the technology
of plant molecular farming, and remain some of the brightest prospects for the success of this …

Development of improved approaches for HIV-1 prevention will likely be required for a
durable end to the global AIDS pandemic. Recent advances in preclinical studies and early …

Development of an effective AIDS vaccine is a global priority. However, the extreme diversity
of HIV type 1 (HIV-1), which is a consequence of its propensity to mutate to escape immune …

Focusing T cell responses on the most vulnerable parts of HIV-1, the functionally conserved
regions of HIV-1 proteins, is likely a key prerequisite for vaccine success. For a T cell …

HIV is a virus that remains a major health concern and results in an infection that has no
cure even after over 30 years since its discovery. As such, HIV vaccine discovery continues …

Objective: The efficacy of therapeutic vaccines against HIV-1 infection has been modest.
New inerts to redirect responses to vulnerable sites are urgently needed to improve these …

Abstract 'Kick and kill'cure strategies aim to induce HIV protein expression in latently infected
cells (kick), and thus trigger their elimination by cytolytic T cells (kill). In the Research in Viral …